It was another busy week for Australia's top brokers. This has led to the release of a number of broker notes.
Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone:
According to a note out of Goldman Sachs, its analysts have retained their buy rating on this biotechnology giant's shares with a trimmed price target of $318.40. Goldman felt that CSL delivered a mixed half year result last week. The broker points out that strong immunoglobulin growth and solid gross margin improvements in the CSL Behring business were overshadowed by a weaker than expected performance from its Seqirus influenza vaccines segment. However, given the importance of the CSL Behring business, Goldman believes investors should be focusing more on its improvements. In addition, it is confident that the company will deliver on its annual double-digit earnings growth target this year and over the medium term. The CSL share price ended the week at $256.90.
A note out of Morgan Stanley reveals that its analysts have retained their overweight rating and $40.00 price target on this pizza chain operator's shares. This follows the release of a promising trading update and the announcement of plans to undertake mass store closures in Japan to improve profitability. Morgan Stanley was pleased with both the plans and the trading update. It notes that its guidance for a net profit before tax of $84 million to $86 million in FY 2025 was a touch ahead of consensus estimates for the period. The Domino's share price was fetching $33.25 at Friday's close.
Analysts at Bell Potter have upgraded this health imaging technology company's shares to a buy rating with an improved price target of $330.00. According to the note, the broker made the move in response to the release of another strong result from Pro Medicus last week. Bell Potter highlights that the company's full stack solution continues to "wipe the floor with competitors." It notes that there have been 10 contract announcements in the last 12 months, including two new academic medical centres clients. Its analysts also advised that they expect further growth in the cardiology space with the first small scale implementation to take place in April. The Pro Medicus share price ended the week at $283.53.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.